United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA)

Gamma-amino butyric acid (GABA) is marketed in the U.S. as a dietary supplement. USP conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nutrients 2021-08, Vol.13 (8), p.2742
Hauptverfasser:	Oketch-Rabah, Hellen A., Madden, Emily F., Roe, Amy L., Betz, Joseph M.
Format:	Artikel
Sprache:	eng
Schlagworte:	adverse effects Adverse events Antihypertensives Blood pressure Butyric acid Case reports Chemical synthesis Dietary supplements Endocrine system Enzymes Fermentation Fermented milk products Food GABA gamma-amino butyric acid Hypotension Lactation Metabolism Metabolites Milk Nervous system Neurotransmitters Plant resistance PMS Premenstrual syndrome Prolactin Review safety review Toxicity Toxicology γ-amino butyric acid γ-Aminobutyric acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Gamma-amino butyric acid (GABA) is marketed in the U.S. as a dietary supplement. USP conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as a natural constituent of fermented milk or soy matrices. Data showed no serious adverse events associated with GABA at intakes up to 18 g/d for 4 days and in longer studies at intakes of 120 mg/d for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (
ISSN:	2072-6643 2072-6643
DOI:	10.3390/nu13082742